ARTICLE | Clinical News
CUDC-907: Phase I started
January 5, 2015 8:00 AM UTC
Curis began an open-label, U.S. Phase I trial to evaluate 3 dosing schedules of oral CUDC-907 in about 60 patients, including those with hormone receptor-positive, HER2-negative breast cancer or midli...